1. Pink Sheet
  2. >>Legal & IP

Opioid Trial Preview: The Claims, Defenses, And Last-Minute Maneuvers

 
• By Brenda Sandburg

Trial opens after settlement proposals by three distributors, Teva and J&J fail to gain support of cities and counties. Distributors want to call former FDA Commissioner Kessler to testify over plaintiffs' objections. Judge rules plaintiffs cannot seek future damages.

3d medical scales sign with included clipping path in jpg file. - Illustration
The opioid bellwether trial in Ohio is the culmination of a decade of legal battles

The long-awaited bellwether trial to determine if drug manufacturers, distributors and pharmacies are culpable in the opioid epidemic and how much they should pay to cover the costs borne by cities and counties begins on 21 October as the parties fail to reach an agreement on proposed settlements.

The litigation is unprecedented in its size and scope and the intense scrutiny it has placed on industry's actions as the epidemic of opioid abuse and addiction intensified and hundreds of thousands of people died from opioid overdoses

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

What MAHA Means For US FDA: Prevention Is Not What You Think

 
• By Michael McCaughan

US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.